Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
VKTX 
Viking Therapeutics Inc (VKTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/29/2025: VKTX (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $89.95
1 Year Target Price $89.95
| 10 | Strong Buy |
| 7 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 83.97% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 07/29/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.73B USD | Price to earnings Ratio - | 1Y Target Price 89.95 |
Price to earnings Ratio - | 1Y Target Price 89.95 | ||
Volume (30-day avg) 19 | Beta 0.61 | 52 Weeks Range 18.92 - 81.73 | Updated Date 07/29/2025 |
52 Weeks Range 18.92 - 81.73 | Updated Date 07/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.54 |
Earnings Date
Report Date 2025-07-22 | When Before Market | Estimate -0.4533 | Actual -0.58 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -14.99% | Return on Equity (TTM) -19.99% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2926326705 | Price to Sales(TTM) - |
Enterprise Value 2926326705 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -71.64 | Shares Outstanding 112445000 | Shares Floating 219964833 |
Shares Outstanding 112445000 | Shares Floating 219964833 | ||
Percent Insiders 2.15 | Percent Institutions 70.06 |
Upturn AI SWOT
Viking Therapeutics Inc
Company Overview
History and Background
Viking Therapeutics Inc. was founded in 2014. It focuses on the development of novel therapies for metabolic and endocrine disorders.
Core Business Areas
- Metabolic Disorders: Development of therapies for non-alcoholic steatohepatitis (NASH), a liver disease associated with obesity and diabetes, and other metabolic conditions.
Leadership and Structure
Viking Therapeutics is led by Brian Lian, Ph.D., as President and CEO. The company has a board of directors and a management team overseeing its research and development activities.
Top Products and Market Share
Key Offerings
- VK2809: VK2809 is an oral thyroid hormone receptor beta (TRu03b2) selective agonist being developed for the treatment of NASH. Market share is dependent on future FDA approval. Competitors include Madrigal Pharmaceuticals (MDGL) and Akero Therapeutics (AKRO).
- VK2735: VK2735 is a dual agonist of the glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) being developed for obesity. Market share is dependent on future FDA approval. Competitors include Eli Lilly (LLY), Novo Nordisk (NVO).
Market Dynamics
Industry Overview
The pharmaceutical industry focused on metabolic disorders is experiencing significant growth due to the increasing prevalence of obesity, diabetes, and related conditions like NASH.
Positioning
Viking Therapeutics is positioned as a clinical-stage biopharmaceutical company focused on developing innovative therapies for underserved metabolic diseases. Its competitive advantage lies in its selective and targeted approaches.
Total Addressable Market (TAM)
The TAM for NASH and obesity treatments is estimated to be in the tens of billions of dollars. Viking is positioning itself to capture a significant share with potentially best-in-class drugs.
Upturn SWOT Analysis
Strengths
- Promising clinical trial results for VK2809 and VK2735
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Clinical-stage company with no approved products
- High cash burn rate
- Reliance on successful clinical trial outcomes
Opportunities
- Potential for FDA approval of VK2809 for NASH
- Expansion of pipeline into other metabolic disorders
- Partnerships or acquisitions by larger pharmaceutical companies
Threats
- Clinical trial failures
- Competition from other companies developing NASH and obesity therapies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- MDGL
- AKRO
- LLY
- NVO
Competitive Landscape
Viking competes with larger pharmaceutical companies with more resources. Its advantage lies in its specialized focus and potentially differentiated therapies.
Growth Trajectory and Initiatives
Historical Growth: Growth is tied to the clinical development and potential commercialization of its pipeline candidates.
Future Projections: Future growth is dependent on successful clinical trials and regulatory approvals. Analyst estimates vary based on the probability of success of its lead compounds.
Recent Initiatives: Advancement of VK2809 and VK2735 through clinical trials; exploration of new indications for its existing pipeline; potential collaborations with other companies.
Summary
Viking Therapeutics is a promising clinical-stage biotech company with potential blockbuster drugs in development for NASH and obesity. Positive clinical trial data has fueled investor interest. However, its success hinges on navigating the risks inherent in drug development, including clinical trial failures and regulatory hurdles. The company will need to manage its cash burn effectively to reach commercialization.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (estimates)
- Industry News Sources
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share data is an estimate based on future projections and may not reflect actual results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Viking Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2015-04-29 | President, CEO & Director Dr. Brian Lian Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 48 | |
Full time employees 48 | |||
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.